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948Oral Symptom Intensity, Health-Related Quality
of Life, and Correlative Salivary Cytokines in Adult
Survivors of Hematopoietic Stem Cell Transplantation
with Oral Chronic Graft-versus-Host Disease
Jane M. Fall-Dickson,1 Sandra A. Mitchell,2 Susan Marden,3 Edward S. Ramsay,4
Jean-Pierre Guadagnini,5 Tianxia Wu,6 Lena St. John,1 Steven Z. Pavletic7 for the National
Institutes of Health Chronic Graft-versus-Host Disease Study GroupOral chronic graft-versus-host disease (cGVHD) is a frequent, clinically significant sequela of allogeneic
hematopoietic stem cell transplantation (HSCT). This study was designed to elucidate relationships among
clinical characteristics of oral cGVHD and related oral pain and oral dryness, salivary proinflammatory
cytokine interleukin (IL)-6 and IL-1a concentrations, and health-related quality of life (HRQL). An under-
standing of the characteristics and correlates of oral cGVHD manifestations and related symptoms, such
as oral dryness, is fundamental to the development of therapeutic interventions. Oral cGVHD severity
was assessed with the Oral Mucositis Rating Scale (OMRS). Oral pain and perceived intensity of oral dryness
were self-reported via a visual analog scale and a numeric rating scale, respectively. HRQL was assessed with
the Functional Assessment of Cancer Therapy-General (FACT-G). Salivary IL-1a and IL-6 concentrations
were measured by enzyme-linked immunosorbent assay. All 42 adult subjects (59% males) had clinician-
assessed oral cGVHD by the OMRS scale (mean score, 18.38 6 12.99; range, 2-46). Oral dryness (in 43%
of subjects; mean OMRS score, 2.566 3.45; range, 0-10) was more prevalent than oral pain (8%; mean score,
0.136 0.47). Salivary IL-6 was associated with oral cGVHD severity (r5 0.49; P\.01), oral ulceration (r5
0.38; P 5 .04), and erythema (r 5 0.63; P\.01). FACT-G total score and physical and emotional well-being
subscale scores were meaningfully lower than U.S. population normative values. Participants with more se-
vere oral cGVHD manifestations had significantly inferior social/family well being (r 5 -0.49; P\.01). Oral
dryness was associated with higher salivary IL-1a (r 5 0.41; P 5 .04) and, controlling for cGVHD severity,
with lower HRQL (r 5 -0.41; P 5 .03). Subjects with moderate to severe oral dryness tended to report
the poorest overall HRQL. This study provides preliminary evidence of the relationship between oral dry-
ness and HRQL, the contribution of oral cGVHD to inferior HRQL, and the association between IL-6 and
oral cGVHD severity, ulceration, and erythema. The high prevalence of oral dryness and its relationship to
HRQL in a sample of subjects with oral cGVHD underscores the importance of improving our evaluation and
management of this symptom in long-term survivors of allogeneic HSCT. The positive associations between
IL-6 and oral cGVHD severity and erythema, as well as the positive trend with oral ulceration, warrant
further exploration of this cytokine as a potential biomarker of active oral cGVHD.
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Biol Blood Marrow Transplant 16:948-956, 2010 949Oral Chronic GVHD Related Symptoms, Quality of Life, and CytokinesINTRODUCTION (Figure 1). Xerostomia, immunosuppressant side ef-Chronic graft-versus-host disease (cGVHD) is
a major complication of allogeneic hematopoietic
stem cell transplantation (HSCT) resulting from an
exaggerated inflammatory mechanism as donor lym-
phocytes encounter foreign antigens on host cells and
mount an inflammatory reaction [1-4]. Approximately
50% of patients who undergo allogeneic HSCT
develop cGVHD [5], with increasing incidence related
to lower treatment-related mortality and changing
HSCT utilization patterns [1]. Approximately 45% of
patients with cGVHD live with these late treatment ef-
fects for a prolonged period [1], and our limited knowl-
edge of the appropriate supportive care needs impedes
the delivery of quality care.
Animal and human models suggest that the under-
lying immunologic mechanisms of cGVHD include
donor-derived alloreactive T lymphocytes; autoreac-
tive T-lymphocytes that evade thymic deletion [6,7];
alterations in absolute numbers, ratios, or kinetics of
lymphocyte subpopulations [8,9], such as regulatory
T lymphocytes [10-14]; and dysregulation of
cytokine expression [15-17]. Elevated levels of
interleukin (IL)-6, IL-1b, IL-1a, IL-1 receptor antag-
onist, tumor necrosis factor alpha (TNF-a), soluble
TNF-receptor II, monocyte chemoattractant protein
1, and soluble B cell activating factor are associated
with autoimmune or chronic inflammatory diseases
that clinically parallel cGVHD [18-25]. Several of
these immune activity mediators are candidate
biomarkers of cGVHD activity [15,16].
Approximately 80% of patients with cGVHDhave
oral involvement, including tissue atrophy and edema,
erythema, lichenoid changes, and oral ulcerationsFigure 1. Erythema and ulceration/pseudomfects, and viral or fungal infection can exacerbate the
severity of discomfort because of oral cGVHD
[4,26,27]. Patients with cGVHD have significantly
reduced stimulated submandibular and sublingual
gland saliva flow rates [28]. This decreased salivary vol-
ume results in decreased salivary immunoglobulin se-
cretion (IgA, IgG, and EGF) [28], possibly increasing
the risk of infection.
cGVHD-related oral pain is prevalent [4,27] and
may occur in association with oral ulceration(s).
cGVHD-related xerostomia, oropharyngeal pain,
and heightened oral sensitivity also may contribute
to decreased nutritional intake and weight loss [29].
Although candidate serum biomarkers of cGVHD
are currently being explored [17], little is known about
cytokine expression in oral tissues involved with
cGVHD. Exploration of the oral tissue cytokine
milieu might yield important insight into the pathobi-
ology of oral cGVHD and inform the rational
development of targeted interventions.
Observational studies have demonstrated that
patientswith cGVHDexperience impairedhealth status
and health-related quality of life (HRQL) [1,30,31].
The extent to which oral cGVHD contributes to these
impairments is unknown. Xerostomia induced by
radiation therapy has a significantly negative impact
on HRQL in patients with head and neck cancer [32-
34] and lymphoma [35,36]. The relationship between
oral cGVHD-related symptoms and HRQL has not
yet beenexamined, however.Patientswithoral cGVHD
may live the remaining years of their lives with the
disease, making effective management essential.
In this descriptive study, we examined the
oral symptom experience, HRQL, and salivaryembrane in a subject with oral cGVHD.
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cohort of patients (n 5 42) with oral cGVHD. The
specific aims of this study were to describe (1) clinical
characteristics of oral cGVHD, (2) cGVHD-related
perceived oral dryness and oral pain intensity, (3)
HRQL, (4) concentrations of salivary IL-6 and
IL-1a, and (5) associations among characteristics of
oral cGVHD, oral dryness, HRQL, and salivary
cytokine expression. Elucidating components of the
symptom experience of patients with oral cGVHD,
as well as their associations with HRQL and the cyto-
kine milieu, is a preliminary step in designing studies
to test novel treatments and supportive care strategies
for this oral disease [37].MATERIALS AND METHODS
This study analyzed cross-sectional data from
a sequentially accrued subsample of patients with
oral cGVHD who were enrolled in the National Can-
cer Institute (NCI)- sponsored cGVHD Natural His-
tory Protocol, ‘‘Prospective Assessment of Clinical and
Biological Factors Determining Outcomes in Patients
with cGVHD’’ (clinicaltrials.gov #NCT00331968).
The study was approved by the NCI’s Institutional
Review Board, National Institutes of Health (NIH).
Patients were referred by their primary transplantation
physician for evaluation by the NIH cGVHD Study
Group. Written informed consent was obtained from
all participants.
The study dentist (J-P G) performed oral
examinations to confirm the clinical diagnosis of oral
cGVHD, and recorded data on self-reported oral
pain and oral dryness during one protocol visit in the
Dental Clinic, Clinical Center, NIH. Stimulated sub-
mandibular/sublingual saliva samples were obtained
during this protocol visit. Submandibular/sublingual
saliva samples also were obtained from a comparison
sample of healthy adult volunteers (mean age, 43.74
years; range, 21-72 years; 57% males; n 5 31). Using
standardized criteria, a summative cGVHD severity
score was derived based on a clinical and diagnostic
evaluation of multiple organ systems, including the
skin, mouth, eyes, liver, lungs, and gastrointestinal sys-
tems, as well as functional capacity, and also gyneco-
logic disease manifestations in women [38].
Measurement of HRQL was completed within 6 48
hours of the Dental Clinic visit.
Research Instruments
Oral cGVHD Characteristics
The Oral Mucositis Rating Scale (OMRS), con-
structed through selection of clinical descriptors of
oral mucosal changes following bone marrow trans-
plantation [39], has been found to be reliable and
valid in classifying oral changes related to cGVHD[27]. The tool divides the oral cavity into 7 distinct
anatomic areas: lips (upper and lower), labial mucosa
(upper and lower), buccal mucosa (right and left),
tongue (dorsal, lateral, and ventral), floor of mouth,
palate (hard and soft), and attached gingiva. These
13 oral cavity areas are clinician-assessed for ery-
thema, atrophy, hyperkeratosis, lichenoid changes,
and edema, and these oral tissue changes are rated
on a scale of 0-3, as compared with normal oral tissue
(0, normal/no change; 1, mild change; 2, moderate
change; and 3, severe change). The extent of ulcera-
tion/pseudomembrane is estimated based on the sur-
face area involved (0, none; 1, .0 but #1 cm2; 2,
.1 cm2 but #2 cm2; and 3, .2 cm2). The total score
is the sum of all OMRS items, with a possible range
of 0-273.
Oral Symptom Intensity
Current oral pain intensity was reported by
subjects using a 10-cm visual analog scale (VAS)
ranging from 0 (‘‘no pain’’) to 10 (‘‘worst possible
pain’’) [40]. Studies have demonstrated high test-
retest reliability for VASs [40]. Current oral dryness
intensity was measured using a verbally administered
10-cm numeric rating scale consisting of a 1-item,
11-point scale with the anchors representing
extremes of the oral dryness continuum, from
0 (‘‘no dryness’’) to 10 (‘‘worst possible dryness’’). A
written numeric rating scale has been shown to be
valid in the measurement of dyspnea [41] and has
demonstrated evidence of reliability, validity, and
responsiveness for pain assessment [42].Health-Related Quality of Life
HRQL was measured with FACT-G version 4
[43]. The 27 items evaluate aspects of physical,
social/family, emotional, and functional well being
on a scale of 0 (‘‘not at all’’) to 4 (‘‘very much’’). Scores
are summed for a total FACT-G score, with a possible
range of 0-108. The FACT-G includes 4 subscales:
physical well being (PWB), social/family well being
(SWB), emotional well being (EWB), and functional
well being (FWB). Higher total FACT-G and subscale
scores indicate better HRQL and greater well being
within these domains. Normative values for the gen-
eral U.S. population and for adults with cancer are
available to aid interpretation [44]. A 2-point differ-
ence in the FACT-G subscale scores and a 5-point dif-
ference in the FACT-G total score represent the
minimum clinically important difference [44]. More
than 50% of the items on the FACT-G assess symp-
toms, underscoring the importance of symptoms in
theHRQL experience. Evidence of reliability and con-
struct validity for the FACT-G has been demonstrated
across a wide range of chronically ill populations
[43,45,46].
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Analysis
Submandibular/sublingual saliva was stimulated
by the bilateral application of 2% citric acid to the
tongue using a cotton-tipped swab. Once the parotid
gland was isolated with cotton gauze, saliva was suc-
tioned from the sublingual area for a total of 1minute,
with 30-second intervals between applications. The
saliva was put into 1.5-mL polypropylene microcen-
trifuge tubes on ice and transported to the research
laboratory. The saliva was aliquoted to 300mL sam-
ples in 0.6 mL tubes, which were stored at 280C.
For analysis, samples were thawed to room tempera-
ture and then centrifuged at 4000 rpm for 10 minutes
at 4C; the supernatant was retained. Salivary
concentrations of IL-1a and IL-6 in both subjects
and healthy volunteers were measured by enzyme-
linked immunosorbent assay (ELISA) (R&D Systems,
Minneapolis, MN).Statistical Analysis
Descriptive statistics were used to characterize the
demographic and clinical profiles of the samples. The
strength and direction of linear relationships between
total OMRS score and clinical characteristics, oral
dryness intensity, FACT-G and subscale scores, and
salivary cytokine concentrations were assessed using
Pearson product moment correlations. Significance
of the correlation between oral dryness and FACT-G
was tested controlling for the overall severity of
cGVHD. Significance was established as P\ .01 to
accommodate an adjustment for multiple compari-
sons. Wilcoxon’s exact 2-sample test was used to test
for differences in oral dryness and HRQL between
subjects with and without opioid use. Scatterplots
were used to evaluate oral dryness and HRQL data
by symptom intensity for linear and nonlinear trends
(Figure 2). Data analysis was done using SAS version
9.1.3 (SAS Institute, Cary, NC) [47].Figure 2. Scatterplots of individual scores of the (A) FACT-G total version 4
classified as none (0), mild (1-3), moderate (4-6), or severe (7-10); n5 29. Highe
0-28), and EWB (range, 0-24) scores represent better HRQL.RESULTS
Demographic Characteristics
Subjects (n5 42) ranged in age from 22 to 61 years,
with a median age of 48.5 years (Table 1). The majority
were male (60%) and White (90%). The subjects had
a median of 36.9 months (range, 5-201 months) from
peripheral blood stem cell (79%) or bone marrow
(19%) transplantation, used primarily to treat a hemato-
logic malignancy (Table 1). A median of 11 months
(range, 1-196 months) had elapsed since the subjects’
cGVHD was diagnosed (Table 2). The subjects had
predominantly moderate (48%) or severe (50%)
cGVHDas assessed by theNIH’s cGVHDGlobal Rat-
ing, with a median of 3 organ systems involved (range,
1-6 systems) (Table 2). Approximately two-thirds of the
subjects were receiving moderate or high levels of sys-
temic immunosuppression (Table 2). Nineteen subjects
were receiving one or more systemic opioids; drugs in-
cluded oxycodone (n 5 13), oxycontin (n 5 4), metha-
done (n 5 2), percocet (n 5 1), morphine (n 5 1),
transcutaneous fentanyl (n 5 1), acetaminophen with
codeine (n 5 1), and dilaudid (n 5 1).Oral cGVHD, Oral Symptoms, and HRQL
Our sample with oral cGVHD had erythema
(91%), lichenoid changes (72%), and ulceration
(56%) (Table 3). Oral dryness (43%; mean OMRS
score, 2.56 6 3.45; range, 0-10) was more prevalent
than oral pain (8%; mean score, 0.13 6 0.47) (Table
3). Previous acute GVHD had little association with
oral dryness (r5 0.16; P5 .03). Subjects receiving opi-
oids did not have significantly greater oral dryness
(Wilcoxon’s exact 2-sample test; P 5 .71) or more im-
pairment in HRQL (P 5 .85) compared with those
who were not receiving these agents. No other demo-
graphic factors were associated with oral dryness.
FACT-G scores and all subscale scores except SWB
score were below the US norm data (Table 3).and (B) FACT-G PWB, EWB, SWB, and FWB subscales by oral dryness,
r FACT-G total score (range, 0-108) and higher PWB, SWB, FWB (range
Table 1. Clinical and Demographic Characteristics of the Sample (n 5 42)
n % Mean (SD) Median Range
Age, years 42 46.1 (12.4) 48.5 20-62
Sex
Male 25 60%
Female 17 40%
Race
Caucasian 38 90%
Non-Caucasian 4 10%
Marital status
Single 8 19%
Married 28 67%
Divorced/widowed/separated 6 14%
Diagnosis
Acute leukemia/myelodysplastic syndrome 15 36%
Chronic leukemia/lymphoma 18 43%
Multiple myeloma 6 14%
Other 3 7%
Conditioning
Myeloablative 17 40%
Reduced intensity 25 60%
Donor type
Related 34 81%
Unrelated 8 19%
Stem cell source
Bone marrow 8 19%
Peripheral blood 33 79%
Unspecified 1 2%
Karnofsky Performance Scale score
<50 2 5%
50-60 2 5%
70-80 26 62%
<80 12 28%
Table 2. cGVHD Characteristics of the Sample
n/N % Mean (SD) Median Range
Time since transplantation, months 38.6 (46.2) 36.9 5-201
Time since cGVHD diagnosis, months 30.9 (44.3) 11 1-196
cGVHD onset
De novo 18/42 43%
Quiescent 6/42 14%
Progressive 18/42 43%
NIH cGVHD Global Rating
Mild 1/40 2%
Moderate 19/40 48%
Severe 20/40 50%
Organ systems involved with cGVHD*
Oral mucosa 42/42 100%
Skin 30/40 75%
Ocular 29/40 73%
Gastrointestinal tract 15/40 38%
Liver 23/40 58%
Lungs 14/40 35%
Joints/Fascis 17/40 43%
Genital (women only)† 9/16 56%
Number of organs (other than oral) involved with cGVHD 3.4 (1.4) 3 1-6
Platelets < 100,000 4/42 9%
Platelets > 100,000 38/42 91%
Intensity of immunosuppression
None 9/42 21%
Mild (single-agent prednisone < 0.5 mg/kg/day) 4/42 10%
Moderate (single-agent prednisone $ 0.5 mg/kg/day, or single
agent/modality ± prednisone $0.5 mg/kg/day)
16/42 38%
High (2 or more agents/modalities ± prednisone $0.5 mg/kg/day) 13/42 31%
*NIH score is missing for 2 patients who were enrolled into the cGHVD Natural History Protocol before scoring system implementation.
†One woman declined gynecologic examination.
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Table 3. Oral Mucositis, Oral Symptoms, and HRQL scores (n 5 42)
Variable Subscale/Domain Mean (SD) Median Range
OMRS score 18.38 (12.99) 12 2-46
Erythema 6.19 (4.75) 5 0-17
Lichenoid changes 3.45 (3.27) 3 0-12
Ulceration/pseudomembrane 1.83 (2.55) 1 0-11
Oral pain VAS 0.13 (0.47) 0 0-2
Oral dryness numeric rating scale 2.56 (3.45) 0 0-10
FACT-G (n 5 40) 74.22 (19.30) 74.5 17-104
PWB 18.08 (6.77) 6-27
EWB 17.83 (4.84) 2-24
FWB 17.15 (6.79) 3-28
SWB 20.97 (6.50) 4-28
OMRS indicates Oral Mucositis Rating Scale; FACT-G, Functional Assessment of Cancer Therapy-General; VAS, visual analog scale; PWB, physical well
being; EWB, emotional well being; FWB, functional well being; SWB, social well being; HRQL, health-related quality of life. OMRS score range, 0-273.
Higher OMRS scores denote more severe oral cGVHD. Oral pain VAS score range, 0-10; oral dryness numeric rating scale range, 0-10. Higher oral pain
and oral dryness scores denote more severe symptoms. FACT-G version 4 possible score range, 0-108. The PWB, SWB, and FWB subscales have score
ranges of 0-28; the EWB subscale has a score range of 0-24. Higher subscale scores indicate better physical, social/family, emotional, and functional well
being. FACT-G total score >80.1, PWB score >22.7, SWB score >19.1, EWB score >19.9, and FWB score >18.5 are interpreted as exceeding the general
US adult population norm data (n ~1600) [49]. FACT-G score >80.9, PWB score >21.3, SWB score >22.1, EWB score >18.7, and FWB score >18.9 are
interpreted as exceeding the US adult cancer patient norm data (n 5 2226) [49].
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Despite the presence of oral dryness, 31 subjects
(73%) were able to produce an adequate amount
($400 mL) of stimulated submandibular/sublingual
saliva for ELISA analysis. In submandibular/sublingual
saliva, mean IL-1a concentration was 85.2 pg/mL
(median, 68 pg/mL; range, 13-250 pg/mL; n 5 29),
and mean IL-6 concentration was 2.48 pg/mL
(median, 1.29 pg/mL; range, 0.100-10 pg/mL;
n 5 29). In submandibular/sublingual saliva of healthy
volunteers, mean IL-1a concentration was 31.97 pg/
mL (range, 6-48.7 pg/mL; n5 23), with 20 of 23 values
below the assay detection limit of 3.9 pg/mL.Mean IL-
6 concentration in submandibular/sublingual saliva of
healthy volunteers was 0.93 pg/mL (range, 0.08-5.14
pg/mL), with 11 of 23 values below the assay’s detection
limit of 0.156 pg/mL.When salivary IL-6 or the IL-1a
levels were not detectable by the ELISA assay kit, the
lowest detectable level was used. There were statisti-
cally significant differences between the subjects’ and
healthy volunteers’ submandibular/sublingual saliva
IL-1a concentrations (P \ .05) and IL-6 concentra-
tions (P\ .001).
Associations Among Oral cGVHD, Oral
Dryness, HRQL, and Salivary Cytokines
Total OMRS score had a low negative association
with the FACT-G SWB subscale (r 5 -0.49; P #.01)
(Table 4). IL-6 had a low positive association with
OMRS score (r 5 0.49; P\ .01) and a moderate pos-
itive association with erythema (r5 0.63, P\ .01), and
a positive trend was seen with oral ulceration (r5 0.38;
P 5 .04). However, no association was found between
clinician-assessed erythema, lichenoid, or ulcerative
cGVHD manifestations and FACT-G total or
subscale scores. Oral pain was not included in theassociation analysis, because only 3 subjects had oral
pain exceeding 0. Oral dryness had a low positive
association with IL-1a (r 5 0.41; P 5 .04). Oral dry-
ness also was associated with lower total FACT-G
score (r 5 -0.41; P 5 .03) and with lower PWB score
(r 5-0.42; P 5 .03) and lower SWB score (r 5 -0.40;
P5 .04), at trend levels. Scatterplots (Figure 2) showed
that subjects with moderate to severe oral dryness
tended to report the lowest HRQL. The association
between oral dryness and impaired HRQL remained
when cGVHD severity was controlled for in the
analysis (P 5 .03).DISCUSSION
This study explored the clinical characteristics and
severity of oral cGVHD, prevalence and intensity of
related oral pain and oral dryness, salivary IL-6 and
IL-1a concentrations, HRQL, and examined associa-
tions among these findings in a sample of adult patients
diagnosed with oral cGVHD. Clinician-assessed oral
cGVHD characteristics and patient-reported symp-
toms were studied separately, as recommended by
the NIH’s cGVHD Study Group Response Criteria
Working Group [48]. Accurate assessment of oral
cGVHD lesions is critical in both clinical research
and practice settings because these lesions may be
the only observed indicator of cGVHD, and they are
a highly predictive index of the presence of systemic
cGVHD [49]. The low association between oral
cGVHD severity and oral dryness in our sample un-
derscores the importance of objective clinical evalua-
tion of oral cGVHD clinical characteristics.
Although more than 50% of our subjects had oral
ulcers, only 2 subjects with oral ulcers reported oral
pain. Possible explanations for these results include
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lowing, accommodation to the symptom experience
in chronically ill patients, and use of opioids. Oral
sensitivity was not assessed in this study, and this
would be a useful addition to future symptom
research in patients with oral cGVHD. Although
prescribed medications may have contributed to per-
ceived oral dryness in this sample, subjects receiving
opioids did not have significantly greater perceived
oral dryness than those not receiving opioids. Oral
dryness is accompanied by a decrease in factors that
act to protect the oral mucosa [28] and maintain
oral cavity homeostasis [50]. The negative trends
between oral dryness and overall HRQL, physical
well being, and social/family well being, as well as
the trend of an association between oral dryness
and higher salivary IL-1a concentration, merit
exploration in a larger sample.
Cytokines play a dynamic role in regulating and
modulating immunologic and inflammatory processes
[51] via cooperative networks that control normal
physiological activity and disease-related threats to ho-
meostasis. The positive association between erythema
and salivary IL-6, an essential mediator of inflamma-
tory response to localized mucosal inflammation
[51,52], should be evaluated empirically as a potential
biomarker of oral cGVHD activity and severity.
Associations between oral cGVHD severity and IL-6
gene polymorphisms have been reported [53]. Signifi-
cant redundant functionality and temporality exist
with cytokines, such that no single cytokine is likely
responsible for controlling a specific cellular function
or physiological process [51]. Therefore, exploration
of the cytokine pathways and crosstalk involved in
the pathogenesis of oral cGVHD is needed to
better elucidate the pathogenesis of oral cGVHD
and molecular mechanisms of related symptoms
[53,54,55]. To date, few studies have examined
candidate biomarkers of organ-specific disease activity
in cGVHD, including disease activity in the oral
cavity. Saliva is easy to procure during clinic visits,
and salivary cytokine profiles also may provide
a marker of overall cGVHD activity, because oral
manifestations are often associated with systemic
cGVHD presenting in the eye, liver, and skin [17].
Although previous studies have described HRQL
in HSCT survivors without cGVHD [56], the impact
of cGVHD on HRQL is not well characterized in
the literature [57]. Our sample reported FACT-G
scores and PWB subscale scores below both general
U.S. adult and adult cancer population normative
values, and EWB subscale scores below U.S. norm
data [44] (Table 3). The fact that these differences
exceeded the threshold of theminimally important dif-
ferences of 2 points on the subscale scores and 5 points
on the FACT-G [44] suggests that these differences
may be clinically meaningful.
Biol Blood Marrow Transplant 16:948-956, 2010 955Oral Chronic GVHD Related Symptoms, Quality of Life, and CytokinesAlthough the generalizability of our results
is limited by the small sample size drawn from a single
institution, the high prevalence of oral dryness (43%)
observed in our sample is in accordance with previous
research. Our finding of a negative association
between oral cGVHD severity and social/family well
being, and the trends observed between oral dryness
and inferior physical well being and social/family
well being, merit further exploration in larger, pro-
spective samples. The fact that the association between
oral dryness and inferior HRQL remained even when
overall cGVHD severity was controlled for suggests
that oral cGVHD and its symptoms may contribute
to impaired HRQL. This hypothesis should be empir-
ically tested using a longitudinal or comparative study
design.
This study also elucidates the association between
the immunobiology of oral cGVHD and the subject’s
symptom experience. Examining relationships among
clinician-assessed characteristics of oral cGVHD, re-
lated oral symptoms, HRQL, and the local proinflam-
matory cytokine milieu is critical to improving our
understanding of the pathobiology and sequelae of
this oral disease. Although candidate serum bio-
markers of cGVHD are being actively explored [17],
continued study of the oral tissue cytokine milieu
and its association with clinician-assessed and patient
reported features of oral cGVHD is needed to inform
the rational development of targeted interventions to
test in clinical trials.ACKNOWLEDGMENTS
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